SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [1] GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns
    Dimitriadis, George D.
    Lambadiari, Vaia
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04) : E52 - E53
  • [2] Management of Type 2 Diabetes Mellitus with Overweight: Focus on SGLT-2 Inhibitors and GLP-1 Receptor Agonists
    Jargin, Sergei V.
    EUROPEAN JOURNAL OF THERAPEUTICS, 2019, 25 (02): : 93 - 96
  • [3] Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Singh, Awadhesh Kumar
    Singh, Ritu
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (06): : 329 - 342
  • [4] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [5] Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Prattichizzo, Francesco
    Candia, Paola de
    Ceriello, Antonio
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 120
  • [6] The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists
    Serowik, Thomas C.
    Pantalone, Kevin M.
    JOURNAL OF OSTEOPATHIC MEDICINE, 2024, 124 (03): : 127 - 135
  • [7] Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists
    Bonaventura, A.
    Carbone, S.
    Dixon, D. L.
    Abbate, A.
    Montecucco, F.
    JOURNAL OF INTERNAL MEDICINE, 2019, 286 (01) : 16 - 31
  • [8] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Lugner, Moa
    Sattar, Naveed
    Miftaraj, Mervete
    Ekelund, Jan
    Franzen, Stefan
    Svensson, Ann-Marie
    Eliasson, Bjoern
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [9] Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis
    Wu, Yaping
    Yang, Zhenxing
    Cao, Qingqing
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (11): : 6852 - 6866
  • [10] Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome
    Premji, Resmi
    Nylen, Eric S.
    Naser, Nejat
    Gandhi, Shruti
    Burman, Kenneth D.
    Sen, Sabyasachi
    METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (06) : 321 - 328
12345